Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
$0.98
-3.3%
$1.07
$0.76
▼
$2.03
$18.82M1.6727,964 shs8,027 shs
Lipocine Inc. stock logo
LPCN
Lipocine
$1.52
-5.0%
$1.82
$1.36
▼
$12.37
$16.83M0.49682,510 shs62,346 shs
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
$3.56
+6.0%
$4.85
$3.25
▼
$23.50
$17.09M1.71255,952 shs7,033 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.30
-15.5%
$0.45
$0.26
▼
$15.40
$3.93M0.61285,954 shs25,161 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
+3.30%-1.94%-0.98%-11.79%-0.98%
Lipocine Inc. stock logo
LPCN
Lipocine
-3.61%+0.63%+2.56%-21.95%-46.67%
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
-5.62%-9.92%-13.85%-28.81%-79.27%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+1.31%-5.41%-24.55%-29.00%-96.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
$0.98
-3.3%
$1.07
$0.76
▼
$2.03
$18.82M1.6727,964 shs8,027 shs
Lipocine Inc. stock logo
LPCN
Lipocine
$1.52
-5.0%
$1.82
$1.36
▼
$12.37
$16.83M0.49682,510 shs62,346 shs
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
$3.56
+6.0%
$4.85
$3.25
▼
$23.50
$17.09M1.71255,952 shs7,033 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.30
-15.5%
$0.45
$0.26
▼
$15.40
$3.93M0.61285,954 shs25,161 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
+3.30%-1.94%-0.98%-11.79%-0.98%
Lipocine Inc. stock logo
LPCN
Lipocine
-3.61%+0.63%+2.56%-21.95%-46.67%
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
-5.62%-9.92%-13.85%-28.81%-79.27%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+1.31%-5.41%-24.55%-29.00%-96.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
2.00
HoldN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
2.00
Hold$4.00163.16% Upside
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
2.60
Moderate Buy$17.33386.89% Upside
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
2.20
Hold$53.3317,677.78% Upside

Current Analyst Ratings Breakdown

Latest RVPH, COCP, LPCN, and QNRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Lipocine Inc. stock logo
LPCN
Lipocine
DowngradeSell (D-) ➝ Sell (E+)
11/12/2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
UpgradeSell (E+) ➝ Sell (D-)
10/29/2026
Lipocine Inc. stock logo
LPCN
Lipocine
UpgradeSell (E+) ➝ Sell (D-)
10/19/2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
Initiated CoverageBuy$18.00
10/16/2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
Reiterated RatingSell (E+)
10/12/2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
Initiated CoverageBuy$14.00
10/12/2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
Initiated CoverageBuy$14.00
10/9/2026
Lipocine Inc. stock logo
LPCN
Lipocine
DowngradeSell (D-) ➝ Sell (E+)
10/9/2026
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
Reiterated RatingBuy
9/24/2026
Lipocine Inc. stock logo
LPCN
Lipocine
UpgradeSell (E+) ➝ Sell (D-)
9/23/2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
Initiated CoverageBuy$20.00
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/AN/AN/AN/A$0.46 per shareN/A
Lipocine Inc. stock logo
LPCN
Lipocine
$1.98M8.50N/AN/A$1.91 per share0.80
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
N/AN/AN/AN/A$5.97 per shareN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/A$1.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
-$8.83M-$0.76N/AN/AN/AN/A-295.88%-156.05%N/A
Lipocine Inc. stock logo
LPCN
Lipocine
-$9.63M-$1.28N/AN/AN/A-249.23%-46.52%-41.75%N/A
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
-$15.81M-$19.44N/AN/AN/AN/A-227.75%-149.97%N/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$19.86M-$1.85N/AN/AN/AN/A-391.58%-119.08%N/A

Latest RVPH, COCP, LPCN, and QNRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q3 2026
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
-$0.18-$0.20-$0.02-$0.20$0.11 million$0.11 million
11/12/2026Q3 2026
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.29-$0.17+$0.12N/AN/AN/A
11/5/2026Q3 2026
Lipocine Inc. stock logo
LPCN
Lipocine
-$0.39-$0.08+$0.31-$0.08$0.16 million$2.29 million
11/5/2026Q3 2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
-$1.5157-$0.97+$0.5457-$0.97N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/AN/AN/AN/AN/A
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
N/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/A
1.24
1.24
Lipocine Inc. stock logo
LPCN
Lipocine
N/A
11.36
11.36
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
N/A
7.20
7.20
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/A
2.08
2.08

Institutional Ownership

CompanyInstitutional Ownership
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
6.72%
Lipocine Inc. stock logo
LPCN
Lipocine
9.11%
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
8.63%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
63.18%

Insider Ownership

CompanyInsider Ownership
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
39.40%
Lipocine Inc. stock logo
LPCN
Lipocine
4.69%
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
7.54%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
8.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
1019.26 million11.67 millionNot Optionable
Lipocine Inc. stock logo
LPCN
Lipocine
1411.07 million10.55 millionNo Data
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
44.80 million4.44 millionNot Optionable
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
1413.11 million11.67 millionNo Data

Recent News About These Companies

RVPH: FDA Feedback on New Formulation Imminent
RVPH: Patent Filed for New Formulation

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cocrystal Pharma stock logo

Cocrystal Pharma NASDAQ:COCP

$0.98 -0.03 (-3.28%)
Closing price 04:00 PM Eastern
Extended Trading
$0.98 +0.01 (+0.83%)
As of 05:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Lipocine stock logo

Lipocine NASDAQ:LPCN

$1.52 -0.08 (-5.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.52 +0.00 (+0.33%)
As of 06:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Quoin Pharmaceuticals stock logo

Quoin Pharmaceuticals NASDAQ:QNRX

$3.56 +0.20 (+5.95%)
Closing price 04:00 PM Eastern
Extended Trading
$3.53 -0.03 (-0.79%)
As of 06:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Reviva Pharmaceuticals stock logo

Reviva Pharmaceuticals NASDAQ:RVPH

$0.30 -0.06 (-15.49%)
As of 03:47 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.